Physician profile
Jada Lovick
NPI 1265278329
$1,308.06
in general payments reported to CMS, 2019-2025
14 companies · $835 in 2025
The $835 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $22.75 · 2024: $450 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.06 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $411.82 | 2024-2025 | Austedo Xr, Austedo Xr |
| Indivior INC. | $213.08 | 2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $144.00 | 2024 | Spravato |
| Novo Nordisk INC | $134.95 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Braeburn INC. | $82.23 | 2024-2025 | Brixadi |
| Alkermes, INC. | $64.77 | 2024-2025 | Vivitrol |
| Abbvie INC. | $59.94 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $55.61 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $34.40 | 2025 | |
| Astellas Pharma US INC | $22.78 | 2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.75 | 2023 | Caplyta |
| Boston Scientific Corporation | $21.93 | 2025 | Wavewriter Alpha Prime 16 |
| Axsome Therapeutics, INC. | $20.95 | 2025 | Auvelity |
| Lundbeck LLC | $18.85 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jada Lovick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.